Zeng Qi, Gong Yusheng, Jiao Wenhao, Xu Jiarong, Chen Xiuli, Xu Rengui, Liu Yuan, Liang Xinting, Li Guanyue, Liu Jiajing, He Linxi, Li Wenhao, Zhang Xiaoxia, Chen Xiaoyuan, Chen Wei
Department of Pharmacology, School of Basic Medicine, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Hubei Key Laboratory for Drug Target Research and Pharmacodynamic Evaluation, Huazhong University of Science and Technology, Wuhan 430030, China.
Sci Adv. 2025 Jun 27;11(26):eadv8734. doi: 10.1126/sciadv.adv8734. Epub 2025 Jun 25.
Conventional drug delivery methods for chronic disease often suffer from low potency and poor patient compliance, while current advanced devices face limitations because of bulkiness, frequent implantation needs, inflammation risk, and lack of precise control. To overcome these challenges, we developed the SUSTAIN-a smart, ultra-long-lasting, sequentially triggerable, and artfully implantable nozzle system. The SUSTAIN integrates an osmotic pressure-triggered module, an airflow-generated T-pipe (AGT), and a drug infusion pump (DIP) for controlled subcutaneous drug release. The AGT enables tunable dosing by varying NaHCO/KHPO powder amounts, while shear thinning of the β-cyclodextrin/Pluronic F-127 hydrogel in the DIP ensures sustained drug infusion. In vivo studies show that the SUSTAIN delivers at least four doses of levothyroxine sodium over 10 days and three doses of semaglutide over 42 days, maintaining effective blood drug levels with minimal invasiveness. This system presents a highly promising solution for improving therapeutic outcomes and convenience in chronic disease management.
用于慢性病的传统药物递送方法往往效力低下且患者依从性差，而当前的先进设备由于体积庞大、需要频繁植入、存在炎症风险以及缺乏精确控制等问题而面临局限。为了克服这些挑战，我们开发了SUSTAIN——一种智能、超长效、可顺序触发且巧妙可植入的喷嘴系统。SUSTAIN集成了一个渗透压触发模块、一个气流产生的T型管（AGT）和一个药物输注泵（DIP），用于皮下药物的可控释放。AGT通过改变NaHCO/KHPO粉末量实现可调剂量给药，而DIP中β-环糊精/泊洛沙姆F-127水凝胶的剪切变稀确保了药物的持续输注。体内研究表明，SUSTAIN在10天内递送至少四剂左甲状腺素钠，在42天内递送三剂司美格鲁肽，以最小的侵入性维持有效的血药水平。该系统为改善慢性病管理的治疗效果和便利性提供了一个极有前景的解决方案。
